Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
11.11
-0.04 (-0.36%)
May 5, 2026, 12:20 PM EDT - Market open
Telix Pharmaceuticals Revenue
In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 122.47% growth.
Revenue (ttm)
$803.79M
Revenue Growth
+66.17%
P/S Ratio
4.67
Revenue / Employee
$678,880
Employees
1,184
Market Cap
3.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Dec 31, 2023 | 332.98M | 224.03M | 205.64% |
| Dec 31, 2022 | 108.95M | 103.42M | 1,873.25% |
| Dec 31, 2021 | 5.52M | 1.51M | 37.53% |
| Dec 31, 2020 | 4.01M | 1.57M | 64.21% |
| Dec 31, 2019 | 2.44M | 2.31M | 1,680.89% |
| Dec 31, 2018 | 137.28K | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Catalyst Pharmaceuticals | 588.99M |
| Travere Therapeutics | 490.73M |
| Arcus Biosciences | 247.00M |
| Tango Therapeutics | 62.38M |
| NewAmsterdam Pharma Company | 22.50M |
| Crinetics Pharmaceuticals | 7.70M |
TLX News
- 19 hours ago - New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC - GlobeNewsWire
- 4 days ago - Telix Presents Phase 2 OPTIMAL-PSMA Dosimetry Data For TLX597-Tx In Prostate Cancer Treatment - Nasdaq
- 4 days ago - TLX101-Px (Pixlumi®) MAA Accepted in Europe - GlobeNewsWire
- 5 days ago - Telix Pharmaceuticals Transcript: Status update - Transcripts
- 5 days ago - OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer - GlobeNewsWire
- 7 days ago - Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - GlobeNewsWire
- 13 days ago - ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026 - GlobeNewsWire
- 20 days ago - Telix Pharma Doses First Patient In Phase 3 IPAX BrIGHT Trial Of TLX101-Tx; Prices $600 Mln Bonds - Nasdaq